These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 17608710

  • 1. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS, Kim HJ, Lee S, Eom KS, Min WS, Lee JW, Kim CC.
    Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
    [Abstract] [Full Text] [Related]

  • 2. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, Min CK, Lee JW, Min WS, Kim CC.
    Cancer; 2009 Feb 01; 115(3):561-70. PubMed ID: 19117346
    [Abstract] [Full Text] [Related]

  • 3. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Haematologica; 2008 Dec 01; 93(12):1792-6. PubMed ID: 18838477
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A.
    Leukemia; 2003 Feb 01; 17(2):290-7. PubMed ID: 12592325
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA, Pan Q, Ladanyi M, Steinherz PG.
    Cancer; 2003 Dec 15; 98(12):2643-50. PubMed ID: 14669284
    [Abstract] [Full Text] [Related]

  • 6. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
    Medeiros BC, Chun K, Kamel-Reid S, Lipton J.
    Am J Hematol; 2007 Aug 15; 82(8):758-60. PubMed ID: 17301975
    [Abstract] [Full Text] [Related]

  • 7. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group.
    Br J Haematol; 2008 Nov 15; 143(4):503-10. PubMed ID: 18986386
    [Abstract] [Full Text] [Related]

  • 8. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Qiu JY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 15; 26(1):23-6. PubMed ID: 15946504
    [Abstract] [Full Text] [Related]

  • 9. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
    IMAHASHI N, TOKUNAGA M, NISHIWAKI S, YANAGISAWA M, OZAWA Y, MIYAMURA K.
    Rinsho Ketsueki; 2009 Nov 15; 50(11):1612-5. PubMed ID: 20009435
    [Abstract] [Full Text] [Related]

  • 10. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T.
    J Clin Oncol; 2005 Oct 20; 23(30):7583-93. PubMed ID: 16234522
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up of patients with chronic myeloid leukemia having received autologous stem cell transplantation.
    Hackanson B, Waller CF.
    Ann Hematol; 2011 Apr 20; 90(4):395-9. PubMed ID: 20922524
    [Abstract] [Full Text] [Related]

  • 12. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia.
    Sun J, Wang Z, Luo Y, Tan Y, Allan DS, Huang H.
    Acta Haematol; 2012 Apr 20; 127(3):143-8. PubMed ID: 22248505
    [Abstract] [Full Text] [Related]

  • 13. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group.
    J Clin Oncol; 2006 Jan 20; 24(3):460-6. PubMed ID: 16344315
    [Abstract] [Full Text] [Related]

  • 14. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ.
    Haematologica; 2006 May 20; 91(5):663-6. PubMed ID: 16627251
    [Abstract] [Full Text] [Related]

  • 15. [Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].
    Meng FY, Sun J, Liu QF, Xu D, Yang LJ, Song LL, Liu XL, Xu B, Zhou SY.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Dec 20; 23(12):1301-2, 1306. PubMed ID: 14678896
    [Abstract] [Full Text] [Related]

  • 16. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S, Kim DW, Kim YJ, Chung NG, Kim YL, Hwang JY, Kim CC.
    Blood; 2003 Oct 15; 102(8):3068-70. PubMed ID: 12842984
    [Abstract] [Full Text] [Related]

  • 17. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W, Segel GB, Lichtman MA.
    Blood Cells Mol Dis; 2006 Oct 15; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [Abstract] [Full Text] [Related]

  • 18. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
    Colombat M, Fort MP, Chollet C, Marit G, Roche C, Preudhomme C, Reiffers J, Praloran V, Mahon FX.
    Haematologica; 2006 Feb 15; 91(2):162-8. PubMed ID: 16461299
    [Abstract] [Full Text] [Related]

  • 19. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z, Zhao L, Chen G, Wu D, Qiu H, Tang X, Fu C, Jin Z, Chen F, Xue S, Sun A.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb 15; 35(2):114-9. PubMed ID: 24606651
    [Abstract] [Full Text] [Related]

  • 20. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
    Perz JB, Khorashad JS, Marin D, Apperley JF, Olavarria E.
    Haematologica; 2006 Aug 15; 91(8):1145-6. PubMed ID: 16870551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.